Triptorelin

Triptorelin is a potent GnRH agonist used to suppress gonadotropin secretion and modulate the HPG axis, with community use primarily focused on hormonal suppression and fertility protocols. While clinician-tier guidance suggests 100 µg daily, community reports show a wide range of dosing from 200 µg to 11.25 mg without standardized cycling. Injection-site reactions are frequently reported by users, and the broader evidence base for exploratory indications remains thin, as many of these applications lack posted results.

Half-life~2.8 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.54.81.52.73.01.0

Research Evidence

Evidence shape

Triptorelin carries a high evidence tier, supported by extensive clinical data primarily focused on prostate cancer, infertility, and precocious puberty. With 161 registered trials and 46 distinct sponsors, the research base is broad, though it relies on a significant volume of exploratory or single-trial investigations across 66 mapped indications. While the strongest trials reach Phase 3 standards, the vast majority of these indications remain thin, reflecting a pattern of highly specialized clinical testing rather than widespread, multi-trial validation across the entire spectrum of studied conditions.

Depthhow much
161 registered trials
74 completed · 27 with posted results · 27 recruiting / active · combined n=9566
Breadthhow many areas
66 indications mapped
12 with results · 52 thin / exploratory · 1 animal-only · 40 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
2 blinded with results · 46 distinct sponsors · AE rows aggregated from 17 trials · 44 linked publications on registered trials
Breadth and depth180 rows captured
Human
direct clinical signal
161
Animal
translational support
9
In vitro
mechanistic support
10
HighMediumLow

Anecdotal efficacy

Triptorelin side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
NEW ERA Peptides
US
10 mg
$50.00
$5/mg
2
Direct Peptides Europe
Europe
2 mg
$14.78
$7.38/mg
3
peptidesourcehub.com
CN
10 mg
$229.90
$22.99/mg
4
Huaian Hanyou Peptide
China
2 mg
$49.00
$24.5/mg
5
CenexalabsCode GROUNDTRUT
US
2 mg
$59.99
$30/mg
6
Adaptog Research
GB
10 mg
$370.46
$37.05/mg

price offers can be sorted by column · 1 out-of-stock offer not shown

Some links are affiliate links. This never affects our rankings or inclusion.

Triptorelin dosing & protocol

How Triptorelin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 74
Typical dose
11.3 mg1 mg – 22.5 mg
typical
0
5 mg
10 mg
15 mg
20 mg
25 mg
distribution of 33 reported doses · darker = more
Frequency
daily
Route
subQ

In research trials, triptorelin was administered subcutaneously at daily doses ranging from 1 mg to 22.5 mg, with a typical dose of about 11.3 mg.

74 sources
Clinician practice
Doctor & published-protocol guidance · n = 1
Typical dose
100 µg
typical
0
5 mg
10 mg
15 mg
20 mg
25 mg
across 1 dosed source · darker = more agree
By reported cadence
Daily100 µg · n=1
Frequency
daily
Route
subQ

In clinician practice, triptorelin is typically administered as 100 mcg subcutaneously once daily; no specific cycling regimen is documented for this tier.

1 source
Anecdotal
Community-reported real-world use · n = 10
Typical dose
11.3 mg200 µg – 11.3 mg
typical
0
5 mg
10 mg
15 mg
20 mg
25 mg
distribution of 10 reported doses · darker = more
Frequency
unspecified
Route
subQ

Most community reports give 11.25 mg subcutaneously without a set schedule; a minority report 200 mcg doses, and a few dose every 84 days (≈ every 3 months).

10 sources

Regulatory safety notes

Warnings and precautions
  • • Hypersensitivity: Anaphylactic shock, hypersensitivity, and angioedema have been reported. In the event of a reaction, discontinue TRELSTAR and initiate appropriate medical management.
  • • Tumor Flare: Transient increase in serum testosterone levels can occur within the first few weeks of treatment. This may worsen prostate cancer and result in spinal cord compression and urinary tract obstruction. Monitor patients at risk and manage as appropr…
  • • Metabolic Syndrome: The use of GnRH agonists may lead to an increased risk of metabolic changes such as hyperglycemia, diabetes, hyperlipidemia, and non-alcoholic fatty liver disease. Monitor for signs and symptoms of metabolic syndrome including lipids, bloo…
  • • Cardiovascular Diseases: Increased risk of myocardial infarction, sudden cardiac death and stroke has been reported in men. Monitor for cardiovascular disease and manage according to current clinical practice.
  • • Convulsions: Convulsions have occurred in patients treated with GnRH analogs (including TRELSTAR) with or without a history of predisposing factors. Manage patients who experience convulsions according to institutional guidelines. Severe Cutaneous Adverse Rea…
  • • Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. Consider risks and benefits.
  • • Embryo-Fetal Toxicity: TRELSTAR may cause fetal harm. (5.10 , 8.1)
Contraindications
  • • Known hypersensitivity to triptorelin or any other component of the product, or other GnRH agonists or GnRH.
Drug interactions
  • • No drug-drug interaction studies involving TRELSTAR have been conducted. Human pharmacokinetic data with triptorelin suggest that C-terminal fragments produced by tissue degradation are either degraded completely within tissues, are rapidly degraded further i…

Related peptides

PT-141Kisspeptin-10HCGOxytocinGonadorelin